(NASDAQ: VTRS) Viatris's forecast annual revenue growth rate of 3.32% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.32%.
Viatris's revenue in 2026 is $14,726,900,000.On average, 14 Wall Street analysts forecast VTRS's revenue for 2026 to be $17,320,638,045,732, with the lowest VTRS revenue forecast at $16,553,659,832,031, and the highest VTRS revenue forecast at $17,967,238,512,888. On average, 14 Wall Street analysts forecast VTRS's revenue for 2027 to be $18,001,632,154,758, with the lowest VTRS revenue forecast at $16,757,728,773,793, and the highest VTRS revenue forecast at $19,394,574,650,493.
In 2028, VTRS is forecast to generate $18,603,520,887,483 in revenue, with the lowest revenue forecast at $17,254,143,671,450 and the highest revenue forecast at $20,126,012,767,595.